Update on hepatitis C: Direct-acting antivirals

doi:10.4254/wjh.v7.i28.2829

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 28

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8238)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

715

WORD

230

HTML

4162

Tables (1-1)

211

Sum=5318

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1098

Download

1822

Sum=2920

Dec 8, 2015 (publication date) through Nov 3, 2024

Times Cited of This Article

Times Cited (29)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Dec 8, 2015; 7(28): 2829-2833
Published online Dec 8, 2015. doi: 10.4254/wjh.v7.i28.2829

Table 1 Direct-acting antiviral-based regimens for treatment-naïve hepatitis C virus-infected patients

Genotype	Recommended regimens options
GT1a	SOF/LDV × 12 wk
	PrOD + RBV × 12 wk (no cirrhosis) - 24 wk (cirrhosis)
	SOF + SMV ± RBV × 12 wk (no cirrhosis) - 24 wk (cirrhosis without Q80K variant)
	SOF + DCV × 12 wk (no cirrhosis) - 24 wk (cirrhosis ± RBV)
GT1b	SOF/LDV × 12 wk
	PrOD + RBV × 12 wk
	SOF + SMV ± RBV × 12 wk (no cirrhosis) - 24 wk (cirrhosis)
	SOF + DCV × 12 wk (no cirrhosis) - 24 wk (cirrhosis ± RBV)
GT2	SOF + RBV × 12 wk (no cirrhosis) - 16 wk (cirrhosis)
	SOF + DCV × 12 wk (RBV intolerant)
GT3	SOF + PegIFN + RBV × 12 wk (PegIFN eligible)
	SOF + DCV × 12 wk (no cirrhosis) - 24 wk (cirrhosis ± RBV)
	SOF + RBV × 24 wk (PegIFN ineligible)
GT4	SOF/LDV × 12 wk
	PrO + RBV × 12 wk
	SOF + RBV × 24 wk
	SOF + PegIFN + RBV × 12 wk
	SOF + SMV ± RBV × 12 wk
GT5	SOF/LDV × 12 wk
	SOF + PegIFN + RBV × 12 wk
GT6	SOF/LDV × 12 wk
	SOF + PegIFN + RBV × 12 wk

GT: Genotype; SOF: Sofosbuvir; LDV: Ledipasvir; PrOD: Paritaprevir + ritonavir + ombitasvir + dasabuvir; RBV: Ribavirin; SMV: Simeprevir; DCV: Daclatasvir; PegIFN: Pegylated interferon.

Citation: Seifert LL, Perumpail RB, Ahmed A. Update on hepatitis C: Direct-acting antivirals. World J Hepatol 2015; 7(28): 2829-2833
URL: https://www.wjgnet.com/1948-5182/full/v7/i28/2829.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i28.2829